Strides buys soft gel capsule facility in U.S.

Capsules
Strides says a new soft gel facility it has bought in the U.S. will give it much more capacity and compliments its other facilities. (Pixabay)

Strides Pharma has picked up a soft gel manufacturing facility in the U.S. from Micelle BioPharma for very little but intends to invest in it. 

The Indian drugmaker said today that it bought the Riviera Beach, Florida facility for $500,000 but will invest another $10 million to add other capabilities. It said it is one of the very few manufacturing plants in the U.S. with a soft gel capsule suite for formulations with containment. It also said it has the only  FDA  approved integrated manufacturing‐packaging SGC facility in the U.S.

RELATED: FDA investigators discover key Strides Pharma quality records in shredding room

Strides, which now has eight formulation facility globally, the facility has passed several U.S. inspections.

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

That is not true of all of Strides' other facilities. The FDA last month issued a warning letter to one of Strides' facilities in India. The agency said the drug testing records at a Strides Pharma plant in a shredding room, indicating the facilities had been data integrity issues, as well as other problems. 

Suggested Articles

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.

Novavax will shell out $167 million for Czech manufacturer Praha Vaccines in a move to boost production of a COVID-19 vaccine past 1 billion doses.